A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

Fitzgerald, Kevin, White, Suellen, Borodovsky, Anna, Bettencourt, Brian R., Strahs, Andrew, Clausen, Valerie, Wijngaard, Peter, Horton, Jay D., Taubel, Jorg, Brooks, Ashley, Fernando, Chamikara, Kauffman, Robert S., Kallend, David, Vaishnaw, Akshay, Simon, Amy·2017·New England Journal of Medicine
DOI 10.1056/nejmoa1609243

Cited by (775)

Items 601–700 of 775

  1. A Meta-analysis of the Regulation of Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin-Kexin Type 9 with Inclisiran
    Yihan Li, Kefan Xue, Rui Hu, Xiao Hu, Ran Guo, Guo Hongxia, Gang Li · 2024 · American Journal of Cardiovascular Drugs
  2. Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia
    Su‐Geun Yang, Young-Ah Moon · 2017 · Journal of Pharmaceutical Investigation
  3. Taming preeclampsia at its source
    Ana Sofia Cerdeira, Manu Vatish · 2018 · Nature Biotechnology
  4. Calling for continuous surgical support in Ukraine
    Wireko Andrew Awuah, Jyi Cheng Ng, Lian David, Toufik Abdul‐Rahman, Vladyslav Sikora, Arda Işık · 2023 · International Journal of Surgery
  5. Chemical Modification and Delivery System of Small Interfering RNA Drugs★
    Chen Li, Xiao Si, Jinbo Li, Yan Zhang · 2023 · 化学学报
  6. Idiosyncratic Drug-Induced Liver Injury in a Healthy Patient following PCSK9-Inhibitor Injection
    Björn-Ole Stüben, Dieter Paul Hoyer, Sonia Radünz, Fuat Hakan Saner, Hartmut Schmidt, Hideo Andreas Baba, Juergen Walter Treckmann, Laura Mazilescu · 2024 · Case Reports in Hepatology
  7. Preferential cleavage of upstream targets in concatenated miRNA/siRNA target sites support a 5′-3′ scanning model for RISC target recognition
    Mancang Zhang, Changqing Zhang · 2024 · Biochemical and Biophysical Research Communications
  8. Gene therapy of rare diseases as a milestone in medicine - overview of the field and report on initial experiences in Slovenia
    Urh Grošelj, Marko Kavčič, Ana Drole Torkar, Jan Kafol, Duško Lainšček, Roman Jerala, Matjaž Sever, Samo Zver, Gregor Serša, Maja Čemažar et al. · 2025 · Orphanet Journal of Rare Diseases
  9. New Biotechnological Treatments for Lipid Disorders
    Natalia Valencia‐Enciso, Carlos Olimpo Mendivil · 2018 · Revista de investigaci�n Cl�nica
  10. Inclisiran, the billion-dollar drug, to lower LDL cholesterol – is it worth it?
    Sheila Anne Doggrell · 2020 · Expert Opinion on Pharmacotherapy
  11. Delivery of Oligonucleotide Therapeutics for Macrophage Reprogramming in Inflammatory Diseases
    Dhaval Oza, Mansoor M. Amiji · 2022 · Springer eBooks
  12. The Role of Extracellular Non-coding RNAs in Atherosclerosis
    Yuting Cui, Yating Zhou, Ni Gan, Qiong Xiang, Mengdie Xia, Wei Liao, Xi‐Long Zheng, Juan Peng, Zhi‐Han Tang · 2022 · Journal of Cardiovascular Translational Research
  13. Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics
    Daisuke Ogiya, Zuzana Chyra, Sigitas Jonas Verselis, Morgan O'Keefe, Jacquelyn Cobb, Ivane Abiatari, Srikanth Talluri, Anjana Anilkumar Sithara, Teru Hideshima, Michael Patvin Chu et al. · 2023 · Blood Cancer Journal
  14. ANMCO position paper on the management of hypercholesterolaemia in patients with acute coronary syndrome
    Leonardo De Luca, Carmine Riccio, Alessandro Navazio, Serafina Valente, Manlio Cipriani, Marco Corda, Alfredo De Nardo, Giuseppina Maura Francese, Cosimo Napoletano, Emanuele Tizzani et al. · 2023 · European Heart Journal Supplements
  15. FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
    Mohamed Sayed Hassan · 2017 · Global Cardiology Science and Practice
  16. Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels
    Chuantao Jiang, Hersharan Nischal, Hua Sun, Li Li, Ying Cao, Peng Wei, Jui‐Yoa Chang, Ba-Bie Teng · 2018 · International Journal of Molecular Sciences
  17. Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials
    Conor McQuillan, Alastair P. Gray, Aileen Kearney, Ian B A Menown · 2018 · Advances in Therapy
  18. Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy
    Amir Mohammad Malvandi, Laura Canclini, Anxhela Alliaj, Paolo Magni, Alberto Zambon, Alberico Luigi Catapano · 2020 · Expert Opinion on Biological Therapy
  19. Atherosclerosis Risk Factors
    Axel Haverich, Erin Colleen Boyle · 2019 · Springer eBooks
  20. Allele-Specific Gene Silencing
    Stanley Nattel · 2017 · Circulation Research
  21. Reprogramming of lipid secretome in senescent synovial fibroblasts ameliorate osteoarthritis development
    Jiajie Hu, Dongsheng Yu, Dongmei Wu, Jiasheng Wang, Youzhi Cai, Xiaotian Du, Junfen Ji, Hongwei Ouyang · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  22. RNAi targeting LMAN1-MCFD2 complex promotes anticoagulation in mice
    Siqian Ma, Boyan Liu, Hong Xia Du, Fei Yang, Jingjing Han, Xinqi Huang, Minyang Zhang, Shundong Ji, Miao Jiang · 2024 · Journal of Thrombosis and Thrombolysis
  23. Modified unlocked nucleic acid (MUNA) mitigates off-target effects of small interfering RNAs
    S. Mori, Dhrubajyoti Datta, Lydia A. Perkins, Michelle Jung, Lauren Blair Woods, Alex Eaton, June Qin, Tim Racie, MaryBeth Kim, Dale C. Guenther et al. · 2025 · Nucleic Acids Research
  24. Binding domains of α-synuclein receptors with monomeric/oligomeric α-synuclein: Implications for Parkinson’s disease
    Rosalie Elvira, Jia Sheng Guan, Yuguang Mu, Eng‐King Tan, Zhidong Zhou · 2025 · Biomedicine & Pharmacotherapy
  25. 2′-Ribose-modified nucleotides: A strategy for reducing off-target effects of oligonucleotide drugs
    Honglei Zhang, Yangjian Liu, Jingxuan Ma, Huajie Huang, Wannian Zhang, Donghui Xiu, Teng Ma, Man Zhang, Fei Yu, Gengshen Song · 2026 · Molecular Therapy — Nucleic Acids
  26. Hepatic targeting in ASCVD: integrating lipid lowering and inflammation modulation from statins to gene editing
    Qianqian Xiao, Man Wang, Shitao Wang, Luyun Wang, Hu Ding · 2026 · Journal of Translational Medicine
  27. Are we underestimating the benefits of lipid-lowering therapies?
    Angela Pirillo, Manuela Casula, Elena Olmastroni, Stefano Scotti, Alberto Corsini, Alberico Luigi Catapano · 2026 · Pharmacological Reviews
  28. PCSK9 inhibitors: an updated patent review 2024–2025
    Enrico Mario Alessandro Fassi, Marco Albani, Lorenza d’Adduzio, Erica Ginevra Milano, Carmen Lammi, Giovanni Grazioso · 2026 · Expert Opinion on Therapeutic Patents
  29. Advances in Cardiovascular Care
    William S. Weintraub, Kelvin H. Lee · 2018 · JACC Basic to Translational Science
  30. Cyclosporin A-Induced Dyslipidemia and LDL Receptors
    Maaike Kockx, Leonard Kritharides · 2018 · Elsevier eBooks
  31. Small interfering RNA: potential in real-world clinical practice
    A. Sh. Motrinchuk, Alina R. Kasimova · 2024 · Real-World Data & Evidence
  32. Inclisiran Treatment for Cardiovascular Disease Risk Reduction: A Systematic Review and Meta-Analysis
    Ya‐Fang Chen, Si Li, Meijuan Wang, Mengyuan Wu, Zi-Chen du, Liping Wei · 2024 · Journal of College of Physicians And Surgeons Pakistan
  33. Effect of modification of siRNA molecules delivered with aminopropylsilanol nanoparticles on suppression of A/H5N1 virus in cell culture
    Репкова Марина Николаевна, Oleg Yu. Mazurkov, Ekaterina Igorevna Filippova, Maria Protsenko, Natalia A. Mazurkova, Mariya I. Meschaninova, Asya S. Levina, Valentina F. Zarytova · 2024 · Biochimica et Biophysica Acta (BBA) - General Subjects
  34. A comparative analysis of the safety profiles between inclisiran and other PCSK9 inhibitors from real-world evidence – what have we learned recently?
    Zhou Su, Zuyue Liao, Xiubi Chen, Jiong Tang, Yu Wang · 2024 · Expert Opinion on Drug Safety
  35. Lipid nanocarriers for RNA and DNA therapeutics: Next-generation delivery strategies in precision medicine
    Sunghyun Moon, Jong Bum Lee · 2025 · Journal of Industrial and Engineering Chemistry
  36. Late-breaking Trials from the 2016 American Heart Association's Scientific Sessions
    Kyle D. Buchanan, M. Chadi Alraies, Alexandre Hideo Kajita, Toby Rogers, Edward Koifman, Arie Steinvil · 2016 · Cardiovascular revascularization medicine
  37. Novel Target Study to Cure Cardiovascular Disease regarding Proprotein Converse Subtilisin/Kexin Type 9
    Yingjing Zhao, Weihang Li, Weiye Li, Hong Tao, Yuting Li, Bo Wu, Xinhui Wang, Huasong Zhou, Bo Gao · 2022 · BioMed Research International
  38. Current Understanding of PCSK9 and Its Relevance to Cancer Prognosis and Immune Therapy: A Review
    Morteza Hassandokht Mashhadi, Fahime Taheri, Sadaf Irani, Arshiya Mesbah Mousavi, Ali Mehri, Hossein Javid · 2024 · Iranian journal of pathology
  39. Application of therapeutic nucleic acids and RNA interference to create products for personalised medicine
    Igor P. Shilovskiy, George B. Pasikhov, Smirnov Vv, И.А. Кофиади, Maiia V. Popova, Polina A. Strueva, Musa Rakhimovich Khaitov · 2024 · Biological Products Prevention Diagnosis Treatment
  40. Decoding vascular aging: implications for atherosclerosis progression and clinical intervention
    Ceaser Wankumbu Silumbwe, Xiao‐Man Ji, Ming Xu · 2024 · Exploration of Drug Science
  41. Aproximación práctica del paciente con hipercolesterolemia en España. Documento de posicionamiento de SEMERGEN
    Sergio Cinza‐Sanjurjo, Vicente Pallarés‐Carratalá, Ángel Díaz Rodríguez, David Fierro-González, Miguel Turégano-Yedro, José Polo García · 2025 · Medicina de Familia SEMERGEN
  42. Optimized chemical structure extends silencing duration of therapeutic siRNAs in dividing cancer and immune cells
    Anastasia Kremer, Tatyana Ryaykenen, Xavier Segarra-Visent, Melanie Sauer, Leon Breuer, Yi‐Ying Wu, Qi Tang, David A. Cooper, Dimas Echeverria, Clothilde Philouze et al. · 2025 · Molecular Therapy
  43. RNAi technique, how far is it from pediatrics?
    Getu Zhaori · 2017 · Pediatric Investigation
  44. Challenges and Future in Precision Cardiovascular Medicine
    Sang Hong Baek · 2019 · Cardiovascular Prevention and Pharmacotherapy
  45. Medicinal Chemistry of Oligonucleotide Drugs - Milestones of the Past and Visions for the Future
    Jonathan Hall, Anastasia Ashkinadze, Jan Philipp Becker, Artur Łaski, Eva-Maria Manz, Štefan Moravčík, Sebastian Sjöström, Mathilde Vincent · 2022 · CHIMIA International Journal for Chemistry
  46. RNA therapies for cardiovascular disease
    Ageliki Laina, Nikolaos I. Vlachogiannis, Kimon S. Stamatelopoulos, Konstantinos Stellos · 2022 · Elsevier eBooks
  47. Research Progress in the Clinical Treatment of Familial Hypercholesterolemia
    Jing-Yan Ai, Peng-Cheng Zhao, Wen Zhang, Guo-Wu Rao · 2023 · Current Medicinal Chemistry
  48. Working towards full eradication of lipid-driven cardiovascular risk?
    Nick S. Nurmohamed, Erik S.G. Stroes · 2021 · Netherlands Heart Journal
  49. Inclisiran: a novel drug for the treatment of dyslipidemia
    Abdullah Nadeem, Rabeea Tariq, Areeba Aamir Ali Basaria · 2023 · Annals of Medicine and Surgery
  50. Lysosome Targeting Chimeras (LYTACs) That Engage a Liver-Specific Asialoglycoprotein Receptor for Targeted Protein Degradation
    Green Ahn, Steven M. Banik, Caitlyn L. Miller, Nicholas McIlvain Riley, Jennifer R. Cochran, Carolyn Ruth Bertozzi · 2020 · ChemRxiv
  51. PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
    A. A. Nekipelova, Renad Nikolaevich Alyautdin · 2023 · Safety and Risk of Pharmacotherapy
  52. Eficacia, beneficio y seguridad de inclisiran
    José López‐Miranda · 2024 · Clínica e Investigación en Arteriosclerosis
  53. Depletion of renal cortical collecting duct-secreted PCSK9 in early proteinuria prevents sustained nephrotic syndrome-related hypercholesterolemia
    Eduardo Molina‐Jijón, Itzel Pamela Zavala-Guevara, Stéphanie Gambut, Tania Gómez‐Sierra, Carmen Ávila-Casado, Camille Macé, Lionel C. Clément · 2026 · American Journal of Physiology-Renal Physiology
  54. Piperazine-Derived Diamine Lipid Nanoparticles Targeting to the Liver for Delivering Clustered Regularly Interspaced Short Palindromic Repeat Editing of PCSK9 to Durably Maintain Plasmatic Low-Density Lipoprotein Cholesterol in Low Levels
    Shifeng Zhao, Shiyun Huang, Nan Li, Neng Wang, Zhitao Yu, Xiaoyu Liang, Zhenhuang Yang, Hongchang Guo · 2026 · ACS Applied Bio Materials
  55. Emerging biomedical and pharmaceutical strategies for the treatment of atherosclerosis: from conventional lipid-lowering therapy to nanomedicine
    Angelika Myśliwiec, Dawid Leksa, Dorota Bartusik‐Aebisher, David Aebisher · 2026 · Journal of Applied Biomedicine
  56. Molecular glycoengineering of carbohydrate-functionalized nanocarriers for receptor-mediated targeted drug delivery in cancer
    Dilpreet Singh · 2026 · Carbohydrate Research
  57. Inclisiran - hope in the fight against dyslipidemia
    Paulina KRAWIEC, Karolina MADEJ, Izabela WOLANIN, Bartłomiej ZIELONKA, Ilona KOWALCZYK, Bartłomiej STACHYRA, Marta WOLANIN, Cezary STAWIKOWSKI, Barbara Dengler, Aleksandra Osińska · 2023 · Journal of Education Health and Sport
  58. Non-coding RNA and Atherosclerosis
    Aram Adyan, Evgeny E. Bezsonov, Eugene S. Grebenshchikov, А В Гринев, Denis Bogomolov · 2024 · Gene Expression
  59. The impact of heparin and direct thrombin inhibitors on cell-penetrating polymer siRNA transfection
    Lucas Mota, Max Zhu, John N. Tomeo, Melina Recarey, Nyah Patel, Leena Pradhan‐Nabzdyk, Frank W. LoGerfo, Patric Liang · 2024 · Gene Therapy
  60. Breaking barriers: Innovative therapies for managing homozygous familial hypercholesterolemia
    Shuai-Jie Huang, Ping Hsin Huang, Nan-Nan Song, Xian-hui Jia, Hong‐Li Gao, Zhiyuan Lu, Xiaolan Wen · 2025 · Experimental and Molecular Pathology
  61. RNAi in the Postgenomic Era: Delivery, Drug Design, and Emerging Technologies
    Shyamalima Saikia, Indrani Gogoi, Damini Dey, Karpumpuli Mili, Ankita Purkayastha, Kaushik Kumar Mech, Rajdeep Bora, Kistina Neog, Pankaj Chetia, Minakshi Puzari · 2026 · Springer eBooks
  62. Thio-modification effects on mRNA translation using a PureCap-based capping method
    Zheyu Meng, Yiwei Liu, Yuko Nakashima, Masahito Inagaki, Seigo Kimura, Yukari Kondo, Fumitaka Hashiya, Naoko Abe, Noriko Saito–Tarashima, Noriaki Minakawa et al. · 2026 · RSC Chemical Biology
  63. Adenovirus vector-mediated delivery of the CRISPR-CasRx system enables gene knockdown with suppressed collateral activity
    Yuki OSAKADA, Sota Kidawara, Eiko Sakai, Akira Asayama, Fuminori Sakurai, Kahori Shimizu, Hiroyuki Mizuguchi · 2026 · Molecular Therapy — Nucleic Acids
  64. Inclisiran: new era of lipid-lowering therapy?
    Jan Beneš · 2023 · Cor et Vasa
  65. Polymorphic Variant rs11206510 in PCSK9 and Risk of Coronary Artery Disease in Bulgarians
    Reni Tzveova, Teodora Yaneva-Sirakova, Galya Naydenova Atanasova, Silvia Vandeva, D. Pendicheva-Duhlenska, P. Atanasov, Vanio Mitev, Radka Petrova Kaneva · 2023 · Acta Medica Bulgarica
  66. Trends and hotspots in familial hypercholesterolemia: A bibliometric systematic review from 2002 to 2022
    Liang Chen, Hao Peng, Bolin Wang, Wenyuan Yu, Xiaohang Ding, Mingxin Gao, Yang Yu · 2023 · Medicine
  67. Therapeutic oligonucleotide ASC1R shows excellent tolerability and remarkable efficacy in reducing SARS-CoV-2 mRNA levels in C57BL/6 mice
    Veronika Némethová, Petra Babiakova, Michal Šelc, Kristína Jakič, Lucia Uhelska, Boglarka Teglasova, Peter Makovicky, Andrea Bábelová, Filip Rázga · 2024 · Biomedicine & Pharmacotherapy
  68. Novel Pharmacologic Treatments for Cardiovascular Disease: A Practical Update
    Leo Francis Buckley, Ahmed Mohammed Aldemerdash · 2017 · US Cardiology Review
  69. Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
    Όλγα Παναγιωτοπούλου, Scott T. Chiesa, Dimitrios M. Tousoulis, Marietta Charakida · 2019 · Current Medicinal Chemistry
  70. PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection
    Pratik Pandey, Cuimei Zhao, Ban Liu · 2020 · Methods in molecular biology
  71. Update on Inclisiran for Treatment of Hypercholesterolemia
    Nasser E. Mikhail · 2020 · Journal of Diabetes Research Review & Reports
  72. Inclisiran
    Jonathan Lappin, Andrea Llano · 2021 · Practical Diabetes
  73. Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia
    Frances Hughes-Hubley, Mina Iskander, Angela Cheng-Lai, William H. Frishman, James J. Nawarskas · 2022 · Cardiology in Review
  74. Commencement of Atorvastatin and Ezetimibe Immediately in Patients Presenting with Acute Coronary Syndrome
    Mohammed Sallam, Hossameldin Hassan, Derek Leslie Connolly, Mohammed Shamim Rahman · 2024 · European Cardiology Review
  75. MicroRNA-495 Regulates Collateral Formation And Predicts Myocardial Perfusion In Coronary Chronic Total Occlusion Disease
    Wei Gao, Runda Wu, Jie Yuan, Youming Zhang, Guobing Liu, Jianhui Zhang, Jian Yang, Chenguang Li, Hongcheng Shi, Haibo Liu et al. · 2021 · Research Square
  76. Atherosclerosis: Cholesterol Management
    Scott D. Edmondson, Duane A. Burnett, Harry R. Davis · 2021 · Wiley eBooks
  77. Future Energy Supply, Simulations with Limited Resources
    Léo Benichou · 2011 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
  78. Editorial: the year in lipids and emerging risk factors
    Debabrata Mukherjee, Dimitri P. Mikhailidis · 2022 · Current Opinion in Cardiology
  79. Editorial commentary: Genetics keeps on giving: A possible vaccine for heart disease
    Robert Roberts · 2023 · Trends in Cardiovascular Medicine
  80. Another Way to Target PCSK9
    Harlan M. Krumholz, Sm · 2016 · Journal watch
  81. Starke LDL-Senkung mit nur einer Injektion?
    ob · 2016 · CardioVasc
  82. The onward march of PCSK9 inhibition
    Catrin A. Higgins, Alan Rees · 2017 · Current Opinion in Lipidology
  83. Silencing of the rift valley fever virus s-genome segment transcripts using RNA interference in Sf21 insect cells
    Juliette Rose Ongus, Kiplangat Rono Evans, Alexander Wafula Wamunyokoli Fred · 2017 · AFRICAN JOURNAL OF BIOTECHNOLOGY
  84. Metabolismo del colesterol y mecanismos de acción de los fármacos hipolipemiantes
    Jordi Canals · 2017 · FMC - Formación Médica Continuada en Atención Primaria
  85. Cyclin E1 as a therapeutic target in high grade serous ovarian cancer
    George Au‐Yeung · 2017 · Minerva Access (University of Melbourne)
  86. Le malattie infiammatorie immuno-mediate (IMID) di interesse internistico: fisiopatologia, aspetti clinici e prospettive di terapia
    Andrea Fontanella, Roberto Nardi, M. Masina, Generoso Uomo · 2017 · Italian Journal of Medicine
  87. MODERN APPROACHES TO DYSLIPIDEMIA TREATMENT IN CLINICAL PRACTICE
    Sergey S Yakushin, Е. В. Филиппов, V. S. Petrov · 2017 · Meditsinskiy sovet = Medical Council
  88. The year in cardiology 2017: prevention
    Børge Grønne Nordestgaard, Francesco Cosentino, Ulf Landmesser, Ulrich Laufs · 2018 · Cardiologia Croatica
  89. Commentary: Effects of lipoprotein apheresis on PCSK9 levels
    Ulrich Julius · 2018 · Journal of Cardiology and Cardiovascular Sciences
  90. Emerging Lipid-Lowering Therapies in Secondary Prevention
    Dhruv Mahtta, Salim S. Virani, Anthony A. Bavry · 2019 · Current Cardiovascular Risk Reports
  91. Multidisciplinary Heart Teams for Cutting-Edge Research
    Peter P. Liu, Alison M. Hosey · 2019 · Springer eBooks
  92. Renal Specific RNAi Delivery by Fibrillar Nanoparticle Excipients
    Sam Wong · 2019 · CUNY Academic Works (City University of New York)
  93. An Evaluation of Cell Transfection Strategies to Package RNA in Small Extracellular Vesicles
    Jenna L. McCann · 2020 · uO Research (University of Ottawa)
  94. Familial Hypercholesterolaemia: An Updated Overall Management
    Noor Alicezah Mohd Kasim, Yung An Chua, Hapizah Mohd Nawawi · 2020 · Journal of Clinical and Health Sciences
  95. Genetic and lifestyle risks of cardiovascular disease
    M. Abdullah Said · 2021 · University of Groningen research database (University of Groningen / Centre for Information Technology)
  96. New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges
    Ahmed Bakillah · 2019 · MDPI eBooks
  97. Therapy and clinical trials
    Klaus Georg Parhofer · 2018 · Current Opinion in Lipidology
  98. Key Resources Table
    Ashley M. Karnay · 2018 · Data Archiving and Networked Services (DANS)
  99. PCSK9 Inhibiting siRNA
    R. Scott Wright · 2021 · Stroke revisited
  100. PCSK9 Inhibiting Monoclonal Antibodies
    Zain V. Ahmed, Prerak V. Juthani, Megan L. Lee, Nihar R. Desai · 2021 · Stroke revisited